Presumptive diagnosis of allergic rhinitis may be made in the presence of nasal congestion, sneezing, and itchy nose/palate/eyes with a pattern of allergic triggers.
Definitive diagnosis would require specific IgE reactivity during skin-prick or in vitro testing, but a therapeutic trial may be ordered on the basis of a presumptive clinical diagnosis.
Treatment consists of allergen avoidance where possible and pharmacotherapy (antihistamines, corticosteroids, cromoglicate, decongestants, leukotriene receptor antagonists).
Intranasal corticosteroids remain the single most effective class of medications for treating allergic rhinitis.
Basic environmental modifications directed at reducing exposure to skin flakes or particles from hair or feathers (dander), dust mites, and irritants (e.g., tobacco smoke) are important measures for patients sensitive to these items, and can often be recommended empirically based on the patient's history.
Allergic rhinitis (AR) is a common, yet under-appreciated inflammatory condition of the nasal mucosa, characterised by nasal pruritus, sneezing, rhinorrhoea, and nasal congestion, the last of which is often deemed the most bothersome symptom. Frequently, there is associated palate, throat, ear, and eye itching as well as eye redness, puffiness, and watery discharge. AR is mediated by an IgE-associated response to ubiquitous indoor and/or outdoor environmental allergens.
Allergy and Asthma Medical Group and Research Center
University of California at San Diego School of Medicine
AG has received grant/research support from: Astra Zeneca; Boehringer Ingelheim; Cephalon Circassia Ltd; Clement Clarke Cytos biotechnology; GlaxoSmithKline; Glenmark Specialty, S.A.; Hoffman-LaRoche/Genentech; HRA/Novartis; Janssen Research & Development; Kalypsys , Inc.; Lupin; Merck; Mylan Pharmaceuticals, Inc.; Nestle (Nestec Ltd); Novartis Ono Pharmaceutical Co., Ltd.; Perrigo; Rigel Pharmaceuticals, Inc.; Roxane Laboratories Inc.; Shionogi Inc.; Sunovion TEVA Branded Pharmaceutical Products; UBC (United Biosource Corporation)/Amgen Pharmaceuticals; and sponsorship for pharmaceutical trials from Allergen Research Corporation/Aimmune Therapeutics, Inc. and Astra Zeneca.
Clinical Immunology Coordinator
Division of Rheumatology, Immunology and Allergy
MDL declares that he has no competing interests.
Allergy & Rhinology Department
Royal National TNE Hospital
GS is a consultant/advisory board member for ALK, Britannia Pharmaceuticals, CMP Therapeutics, Groupo Uriach, GSK, Merck, Sanofi-Aventis, Schering Plough, and UCB. She has received research funds from ALK, GSK, UCB, and Schering Plough. She has given talks for ALK, GSK, Merck, Schering Plough, and UCB and has co-written articles for Schering Plough and GSK.
Use of this content is subject to our disclaimer